Jul 8, 2020
This episode tries out a different format from our regularly scheduled programming. We sit down and discuss (and sometimes rant about) our thoughts about Gilead's $3k price tag announcement for remdesivir. What was supposed to be a quick discussion of a current event quickly devolved into broader discussions about drug pricing, patent law, and public opinion.
email: econrxpodcast@gmail.com
Twitter/Instagram: @EconRx
LinkedIn: www.linkedin.com/company/econrx